Q/C Technologies (QCLS) risk factors, FY2024 10-K

Risks Related to our Business

1. 01Our financial statements have been prepared on a going concern basis; we must raise additional capital to fund our operations in order to continue as a going concern
2. 02Any additional capital raised through the sale of equity or equity-backed securities may dilute our stockholders’ ownership percentages and could also result in a decrease in the market value of our equity securities
3. 03The market price of our Common Stock has been and may continue to be subject to significant fluctuations and volatility, and the stockholders of the Company may be unable to resell their shares at a profit and may incur losses
4. 04Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability
5. 05The concentration of the capital stock ownership with insiders of the Company will likely limit the ability of our stockholders to influence corporate matters
6. 06Certain stockholders could attempt to influence changes within the Company, which could adversely affect our operations, financial condition and the value of our Common Stock
7. 07Our largest stockholder maintains the ability to significantly influence all matters submitted to our stockholders for approval
8. 08We must attract and retain highly skilled employees to succeed
9. 09We operate in a highly competitive industry
10. 10If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
11. 11Although we maintain workers’ compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities
12. 12Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security or those of third-party providers

Risks Related to our Product Development and Regulatory Approval

1. 13Clinical drug development is a lengthy, expensive, and inherently uncertain process, and we may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
2. 14If we are unable to develop, obtain regulatory approval for and commercialize Isomyosamine, Supera-CBD or other future product candidates, or if we experience significant delays in doing so, our business will be materially harmed
3. 15We may not have the resources to conduct clinical protocols sufficient to yield data suitable for publication in peer-reviewed journals and our inability to do so in the future could have an adverse effect on marketing our products effectively
4. 16Success in pre-clinical studies and earlier clinical trials for our product candidates may not be indicative of the results that may be obtained in later clinical trials, including our Phase 2 clinical trial for Isomyosamine, which may delay or prevent obtaining regulatory approval
5. 17Even if we complete the necessary pre-clinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek
6. 18The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product
7. 19Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the U.S
8. 20Our development program for Supera-CBD, a synthetic analog of CBD, is in its infancy and subject to substantial uncertainty and may not yield commercial results and is subject to significant regulatory risks
9. 21Further, the success of our prospective Supera-CBD candidate, if any, is subject to a number of constantly-evolving state and federal laws, regulations, and enforcement policies pertaining to the use of CBD
10. 22Negative public perception of cannabis-related businesses, misconceptions about the nature of our business or Supera-MD, and regulatory uncertainties relating to the legality of cannabinoids could each have a material adverse effect on our business, financial condition, and results of operations

Risks Related to Commercialization and Manufacturing

1. 23The commercial success of our product candidates, including Isomyosamine and Supera-CBD, will depend upon their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community
2. 24The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue
3. 25Several companies are focused on developing treatments for immunometabolic dysregulation in treatment of autoimmune disorders

Risks Related to Government Regulation

1. 26We could be adversely affected if healthcare reform measures substantially change the market for medical care or healthcare coverage in the U.S
2. 27We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to comply, the agency can institute a wide variety of enforcement actions which may materially affect our business operations
3. 28The FDA’s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, statutory, regulatory and policy changes and global health concerns

Risks Related to Our Intellectual Property

1. 29Our success largely depends on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their adequate protection
2. 30We may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position
3. 31Our potential strategy of obtaining rights to key technologies through in-licenses may not be successful
4. 32If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
5. 33We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
6. 34Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with our product discovery and development efforts
7. 35We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid
8. 36We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world
9. 37Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 38As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain
11. 39Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
12. 40If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed

Risks Related to Our Preferred Stock

1. 41Under the February 2023 SPA, the Series F-1 Purchase Agreement and Series G Purchase Agreement we are subject to certain restrictive covenants that may make it difficult to procure additional financing
2. 42Offers or availability for sale of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline
3. 43An active trading market for our Common Stock may not be sustained
4. 44We are subject to various internal control reporting requirements under the Sarbanes-Oxley Act. We can provide no assurance that we will at all times in the future be able to report that our internal controls over financial reporting are effective
5. 45We incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results
6. 46If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted
7. 47We may issue additional equity securities in the future, which may result in dilution to existing investors
8. 48We do not anticipate paying cash dividends on our Common Stock and, accordingly, stockholders must rely on stock appreciation for any return on their investment
9. 49If securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our Common Stock could decline
10. 50Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management
11. 51We have been subject to a number of securities litigations, and we may be subject to similar or other litigation in the future